Asst Prof Cheow Lih Feng (right), his former PhD student Dr Elsie Cheruba...
Asst Prof Cheow Lih Feng (right), his former PhD student Dr Elsie Cheruba (left) and their team have developed the Heatrich-BS assay, an affordable and highly sensitive blood test for cancer. This new testing method has strong potential to be used in regular cancer monitoring.

Image source: NUS

News • High-sensitivity blood test

New cancer testing method to make regular monitoring affordable

Scientists from the National University of Singapore (NUS) have discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, this new test sequences clinical samples that have been heated in order to isolate cancer-specific signatures found in a patient’s blood.

The new method provides a promising non-invasive alternative to tissue biopsies. It costs around S$ 50 (€ 35) from start to finish, compared to other sequencing methods that can cost up to S$ 1,000 (over € 700) to conduct. Led by Assistant Professor Cheow Lih Feng, the team comprising researchers from the NUS Department of Biomedical Engineering under the College of Design and Engineering as well as the NUS Institute for Health Innovation & Technology, is now exploring industry partnerships to bring their technology to market. 

The NUS team published their findings in the scientific journal Science Advances, and a patent has also been filed for their discovery. 

“When you have a S$ 50 test, it opens up a lot of avenues because it is affordable, so you can do the test quite regularly,” said Asst Prof Cheow, pointing to the potential for their assay to be used in regular cancer monitoring.

We were performing some unrelated experiments, and one of our researchers heated a sample

Cheow Lih Feng

Current methods of testing for cancers can suffer from a lack of sensitivity or from being too expensive to be used for regular screening. The DNA in our blood, the genetic information that tells our cells how to synthesise proteins and other important biological building blocks, is produced by different organs in our body. Cancer cells also release DNA into the bloodstream that can be detected by analysing blood samples, known as liquid biopsies. However, sifting through all the genetic material in a sample – a method called whole-genome sequencing – can be expensive and labour intensive. Some clinicians instead target cancer-specific signatures in cell-free DNA, almost like hunting for specific faces in a large crowd of people instead of inspecting every single individual. Yet, even such methods can be imperfect, Asst Prof Cheow explained. “Some patients may have cancer signatures that look slightly different and allow them to slip through the screening process,” he said. 

Asst Prof Cheow’s team has discovered a way to discard the non-informative sections in a patient’s DNA to target where most cancer-specific biomarkers are concentrated. Our DNA is made up of molecules known as nucleotides: adenine (A), thymine (T), guanine (G) and cytosine (C). Cancer-specific signatures tend to be concentrated in areas of the genome that have high repetitions of C and G nucleotides, known as CpG islands, that make up only around 1% of our genome. “We were performing some unrelated experiments, and one of our researchers heated a sample,” Asst Prof Cheow said, recounting the team’s accidental discovery that heat destroyed non-informative sections of the genome, but left CpG island largely intact. This allowed them to sequence the remaining genome and detect the presence of cancers for a minute fraction of the average market price. “We are getting a much more sensitive assay at almost the same costs as compared to simple protein biomarker tests,” he said, “Our method really concentrates on sequencing these regions that matter the most.”

The Heatrich-BS assay has been trialed at the National Cancer Centre in Singapore, monitoring patients with colorectal cancer. By comparing the results of their blood analysis with CT scans that imaged the size of patients’ tumours, the team found that there was a high correlation between how much cancer-specific DNA was detected in a patient’s blood sample and the size of their tumours over time. “This way, doctors can monitor patients for their response to treatment and tailor their therapy regimes,” Asst Prof Cheow said. He also pointed out that their method has the potential to work universally across all types of cancer since they all demonstrate the property of enriching CpG islands with cancer-specific biomarkers. “It’s a one-size fits all,” he added. 

The assay may also help accelerate future academic research, helping scientists study different subtypes of cancer for a low cost and therefore improving the development of future cancer diagnoses and therapies. 

Asst Prof Cheow and his team are now exploring ways to commercialise their assay by partnering with pharmaceutical and biotechnology companies that can help bring the Heatrich-BS assay to market. “We are excited about our results and licensing discussions are underway,” he said. 


Source: National University of Singapore

06.12.2022

Read all latest stories

Related articles

Photo

News • Patient response testing

New method predicts which cancer therapies work (and which don't)

A new technology that can study which therapies will work on patients with solid cancerous tumours has been developed by scientists at University College London (UCL). Researchers say the tool, which…

Photo

Article •

Oral vaccination against pancreatic tumours

The world’s first gene cancer therapy study of an innovative oral vaccine is underway at the Surgical Clinic of Heidelberg University Hospital.

Photo

Article • Tissue-engineered glioblastoma model

3D brain tumour in a dish to personalize cancer treatment

It is the size of a common pencil eraser, but it could have a huge impact on the therapy of glioblastoma: Scientists in Virginia have developed a novel 3D tissue-engineered model of the brain tumour…

Related products

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter – DxA 5000

Automation

Beckman Coulter – DxA 5000

Beckman Coulter Diagnostics
Subscribe to Newsletter